Screener
Corcept Therapeutics CORT Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
FAQ
- What is Corcept Therapeutics's free cash flow margin?
- Corcept Therapeutics (CORT) reported free cash flow margin of 12.9% in Q2 2026.
- How has Corcept Therapeutics's free cash flow margin changed year-over-year?
- Corcept Therapeutics's free cash flow margin decreased by 48.9% year-over-year, from 25.2% to 12.9%.
- What is the long-term trend for Corcept Therapeutics's free cash flow margin?
- Over 5 years (2020 to 2025), Corcept Therapeutics's free cash flow margin has grown at a -15.3% compound annual growth rate (CAGR), from 42.6% to 18.6%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about Corcept Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude